knowledge -WSS

knowledge

author：explore 2025-08-26 23:46:44 - browse：81

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb said that it would purchase Mirati Therapeutics, maker of the cancer drug Krazati, for $4.8 billion in cash in a deal that shows the continued interest of large pharmaceutical firms in relatively small “bolt-on” acquisitions.

Bristol said that it would pay $58.00 per share for Mirati, and would hold another $12.00 per share, or a total of $1 billion, to be paid if one of two different applications for an additional use for Krazati is approved within seven years after the merger closes.

Chris Boerner, Bristol’s chief operating officer and CEO-elect, said in a statement that Mirati had several cancer drugs in development that could deliver sales in the latter half of the decade and beyond, when investors worry that Bristol will need new products to sustain its growth.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

WSS

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

Presidential fundraising highlights so far: Trump brings in more than DeSantis

Teachers share how revamped forgiveness program helped with their student loans

TytoCare raises $49 million to build out AI

Bank of America ordered to pay more than $100 million for double charging fees, withholding rewards

Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

explore

knowledge

Wikipedia

Walensky prepares to leave CDC — and Congress — behind

What the cancer research community can learn from the Covid response

Bright Health sells Medicare Advantage business to Molina

DeSantis defends odds vs. Trump, despite early poll gap: 'We've worked really hard'

Duchenne breakthrough therapy leaves behind pioneering families

Teachers share how revamped forgiveness program helped with their student loans

BioMarin wins approval for gene therapy to treat hemophilia A

Attacks on the drug industry will lead to fewer breakthroughs

Peter Hotez and the public health issue of online harassment

ER docs worry over extreme heat as a 'mass casualty event'

explore

Judge agrees to delay next hearing in Trump classified documents case

My superpower is killing ticks

Nevada Republican Sam Brown launching another Senate bid, teeing up marquee race

Biden’s NIH nominee is languishing in Congress

Dramatically reducing cancer deaths requires the PASTEUR Act

White House announces new plan to address the growing threat of xylazine in overdose crisis

hotspot

hotspot

hotspot

focus